同種造血幹細胞移植(SCT)後の移植片対宿主病、血栓性微小血管障害症などの致死的な合併症は、依然として克服すべき障害である。今回、抗血栓作用や免疫調整にかかわる因子発現に影響する遺伝子一塩基多型（SNP）とSCT後転帰の関連性を、日本骨髄バンクの協力を得て国内の非血縁者間SCT症例（ドナーと移植患者約600組）を対象として解析した。結果として、ドナーHO-1 SNP rs2071746 A/AまたはA/T型、ドナーUNC93B1 rs308328 C/C型は移植後合併症を抑え生存率改善に寄与、患者ADAMTS-13 rs2285489 C/C型は無病生存率に悪影響する可能性が考えられた。
Life-threatening complications associated with allogeneic hematopoietic stem cell transplantation (SCT),such as severe infection, graft-versus-host disease (GVHD), and thrombotic microangiopathy, remain obstacles to overcome. We investigated the influence of the HO-1 single-nucleotide polymorphism (SNP) rs2071746 (-413A>T), ADAMTS-13 SNP rs2285489 (C>T), UNC-93 homolog B1 SNP rs308328 (T>C) on transplant outcomes in a cohort of about 600 patients undergoing unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor Program.
As a result, the donor HO-1 A/A or A/T genotype and donor UNC93B1 C/C genotype were associated with a better overall survival. On the other hand, the recipient ADAMTS13 C/C genotype was associated with an increased relapse rate, resulting in a lower disease-free survival rate in the patients with a recipient C/C genotype.
ヘムオキシゲナーゼー1が造血幹細胞移植後治療成績におよぼす効果と新規治療戦略
.png)
ME-PR-MORISHITA-E-kaken 2021-22p.pdf
(354.03KB)
